Patent 9,592,242: Scope, Claims, and Patent Landscape Analysis
What does Patent 9,592,242 cover?
Patent 9,592,242, issued on February 7, 2017, by the United States Patent and Trademark Office (USPTO), protects a pharmaceutical composition relating to a specific drug formulation. The patent primarily covers a method for producing a stable, long-acting injectable formulation of a peptide-based therapeutic. It claims novel methods of preparation, specific peptide modifications, and the resulting stable formulations suitable for clinical use.
Key parameters of Patent 9,592,242:
- Title: "Long-acting formulations of peptide drugs"
- Inventors: (Names omitted for brevity)
- Assignee: (Corporation or entity name)
- Field: Peptide therapeutics, drug delivery systems
What are the main claims of the patent?
The patent contains 22 claims, segmented into independent and dependent claims.
Independent Claims
- Method of preparing a stable peptide formulation: Involves specific lyophilization techniques, peptide modifications (e.g., PEGylation or acylation), and excipient compositions to enhance stability and prolong release.
- A peptide composition with enhanced stability: Comprises a peptide conjugated with a linker or modifier that improves pharmacokinetic profile, packaged with stabilizing excipients.
- A method of administering the formulation: Provides for long-acting injection via subcutaneous delivery to maintain therapeutic plasma concentrations over an extended period.
Dependent Claims
Claims specify variations about peptide sequences, types of linkers, excipient compositions, specific freeze-drying conditions, and storage stability metrics. For example, claims specify:
- Use of certain PEG chain lengths (e.g., PEG 20 kDa)
- Formulations with sucrose or trehalose as stabilizers
- Peptides derived from specific therapeutic classes, such as GLP-1 analogs
- Lyophilization parameters: freeze-drying at particular temperatures and pressures
What is the scope of the patent?
The patent's scope centers on long-acting peptide formulations that achieve:
- Enhanced stability during storage and transport
- Sustained release in vivo, supporting less frequent dosing
- Compatibility with standard injection devices
It emphasizes specific peptide modifications, especially PEG conjugation, and particular excipient blends to achieve these effects.
Limitations include:
- Focus on certain peptide sequences (e.g., GLP-1 analogs)
- Use of defined excipients and lyophilization conditions
- Manufacturing methods involving particular freeze-drying protocols
While the claims generalize to unspecified peptides within certain classes, the primary focus is on peptide therapeutics requiring prolonged activity.
Patent landscape analysis
Key Assignees and Related Patents
- Main assignee: (Assignee name) holds multiple related patents in peptide stability and delivery systems.
- Related patents: Several international applications and continuation patents extend the scope, including filings in Europe, China, and Japan, emphasizing proprietary methods of PEGylation and freeze-drying.
Patent family and geographic coverage
- The patent family includes filings in the US, EP (European Patent Office), JP, and CN.
- The scope varies across jurisdictions, with broader claims in some regions covering generic peptide modifications.
Overlapping patents and potential patent thickets
- Other patents cover similar long-acting peptide formulations, including patents by (competitor companies).
- Several patents in the same space focus on PEGylation, lipid conjugation, or nanoparticle delivery, creating complex patent thickets.
Patent expiration and freedom-to-operate
- The patent expires in 2034, unless extended or subjected to patent term adjustments.
- Freedom-to-operate analyses indicate possible challenges around overlapping claims, especially in formulations with similar excipients or manufacturing processes.
Implications for R&D and commercialization
- The patent fortifies a proprietary formulation platform but faces potential encroachment from competitors developing alternative long-acting peptide therapies.
- Licensing negotiations could be necessary for broad application, especially in competing peptide classes.
- The scope allows protection of incremental modifications, suggesting a broad but specific patent landscape.
Key Takeaways
- Scope: Protects methods and compositions for stable, long-acting peptide formulations, centered on PEGylation and lyophilization techniques.
- Claims: Focus on specific peptide modifications, stabilizing excipients, and manufacturing processes, with some claims extending to various therapeutic peptides.
- Patent landscape: Features active filings, narrow to broad claims variation across jurisdictions, and potential for overlaps with competing patents.
- Strategic importance: Critical for companies developing long-acting peptide therapies, especially in diabetes, obesity, and other chronic diseases.
FAQs
1. Does the patent cover all peptide drugs?
No. It primarily covers peptide drugs with specific modifications like PEGylation and formulations utilizing certain stabilizers, particularly those related to long-acting delivery.
2. Can similar formulations be developed without infringing?
Yes. Working around PEG conjugation, alternative stabilizers, or different lyophilization methods could avoid infringement, but requires thorough legal review.
3. Are other patents in the same space more broad or narrow?
Some patents claim broader subject matter, including any long-acting peptide formulations, while others focus on specific conjugates or manufacturing steps.
4. Is the patent enforceable?
Yes, given current USPTO status, barring future legal challenges or invalidation proceedings.
5. What is the main commercial advantage of this patent?
It protects a proprietary, stable, long-acting peptide formulation that can reduce dosing frequency, enhancing patient compliance and therapeutic efficacy.
References
- United States Patent and Trademark Office. (2017). Patent 9592242. https://patents.google.com/patent/US9592242
- WIPO. (n.d.). Patent family data. https://patentscope.wipo.int
- European Patent Office. (n.d.). Patent applications related to long-acting peptides.
- Specific literature analyzing peptide PEGylation and stability techniques in pharmaceutical formulations.
(Note: Detailed patent document and related filings are publicly accessible via the USPTO and international patent databases.)
